


Supplementary Figure 1. Risk of bias


	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
1997 Lecrubier	?	?	?	?	+	+	?
1999 Ruther	?	?	?	?	+	+	?
2004 Rothschild trial 1	?	?	?	?	+	+	?
2004 Rothschild trial 2	?	?	?	?	+	+	?
2008 Chaput	?	+	+	?	+	+	?
2009 Cutler	+	?	+	?	+	+	+
2009 Weisler	+	?	+	?	+	+	?
2011 Bortnick	?	?	?	+	+	+	?
2012 Papakostas	?	?	?	?	+	+	?
2013 Katila	+	+	+	?	+	+	?
2014 Kennedy	?	?	+	?	+	+	?
2014 McIntyre	?	?	+	+	+	+	?
2014 Wang	+	?	+	?	+	+	?
2016 Suppes	+	+	+	?	?	+	?

Supplementary Figure 2. Study Discontinuation when quetiapine 150 mg/day was used


A. Study discontinuation due to all causes



B. Study discontinuation due to lack of efficacy




C. Study discontinuation due to adverse events




Abbreviation: APM, antipsychotic monotherapy

Supplementary Figure 3. Study Discontinuation when studies including MDD with specific features were excluded


A. Study discontinuation due to all causes



B. Study discontinuation due to lack of efficacy




C. Study discontinuation due to adverse events




Abbreviation: APM, antipsychotic monotherapy

Supplementary Figure 4. Psychopathology

A. HDRS-17




B. MADRS




Abbreviation: APM, antipsychotic monotherapy

Supplementary Figure 5. Psychopathology when quetiapine 150 mg/day was used


A. Primary depression severity scale




B. CGI-S



C. HDRS-17




D. MADRS




Abbreviation: APM, antipsychotic monotherapy

Supplementary Figure 6. Psychopathology when studies including MDD with specific features were excluded


A. Primary depression severity scale




B. CGI-S



C. HDRS-17




D. MADRS




Abbreviation: APM, antipsychotic monotherapy

Supplementary Figure 7. Adverse events


A. Akathisia




B. Blurred vision




C. Constipation




D. Diarrhea




E. Dizziness




F. Dry mouth




G. Dyspepsia




H. Extrapyramidal symptoms




I. Fatigue




J. Headache




K. Hyperhidrosis




L. Increased appetite




M. Insomnia




N. Irritability




O. Myalgia




P. Nasopharyngitis




Q. Nausea




R. Palpitation




S. Sedation




T. Sexual dysfunction




U. Somnolence



V. Vomiting



W. Weight gain



Abbreviation: APM, antipsychotic monotherapy